

--13. A method to elicit an antitumor immune response to prostate tumors in a subject, which method comprises administering to said subject at least one active ingredient formulated for administration to said subject,

wherein said active ingredient comprises or expresses at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof,

wherein said active ingredient is an immunologically reactive portion of human prostate-specific antigen (PSA); or

human prostate-specific membrane antigen (PSMA) or an immunologically effective portion thereof; or

prostatic acid phosphatase (PAP) or an immunologically reactive portion thereof; or mixtures of the foregoing; or

is a nucleic acid that generates said antigen or antigens *in situ*.

14. The method of claim 13 wherein said active ingredient is a protein which is said portion of human PSA.

15. The method of claim 13 wherein said active ingredient is human PSMA or said portion thereof.

16. The method of claim 13 wherein said active ingredient is PAP or said portion thereof.

17. The method of claim 13 wherein said active ingredient is a nucleic acid which generates said portion of human PSA *in situ*.

18. The method of claim 13 wherein said active ingredient is a nucleic acid that generates PSMA or said portion thereof *in situ*.

19. The method of claim 13 wherein said active ingredient is a nucleic acid that generates said PAP or said portion thereof *in situ*.